Solara Active Pharma Sciences Limited has informed the Exchange regarding interalia, to consider and approve the audited Standalone and Consolidated Financial Results for the year ended ....
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 14.3 pts more than Nifty Microcap 250 and 14.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Solara Active Pharma Sciences reported consolidated revenue of Rs. 1,369 Crores for FY 2025-26, up 6.6% from Rs. 1,284 Crores in the previous year. However, the company posted a net loss of Rs. 7.41 Crores compared to a profit of Rs. 0.54 Crores in FY 2024-25. The loss was primarily due to an exceptional item of Rs. 5.89 Crores related to gratuity and compensated absences under new labour codes. The company has accumulated losses of Rs. 319.33 Crores, and its net current liabilities exceed current assets by Rs. 35.81 Crores. The board has approved preparing accounts on a going concern basis, citing a rights issue to raise Rs. 135 Crores more and expected renewal of working capital facilities. Q4 FY26 showed a profit of Rs. 9.60 Crores. Auditors gave unmodified opinions on both standalone and consolidated results.
The company swung to a loss in FY26 despite revenue growth, raising concerns about profitability. High accumulated losses and negative working capital signal financial stress, though the rights issue proceeds and positive operating cash flow of Rs. 153 Crores provide some buffer. Shareholders should monitor the final rights issue collection and business restructuring plans.